OmniAb Inc

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. The firm’s platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

OmniAb Inc reports robust Q4 earnings, poised for biotech innovation

OmniAb Inc delivered strong financial performance in Q4 2022, showcasing revenue growth and a healthy cash position. The company's focus on innovation, diverse platform, and strategic partnerships position them for continued success. While challenges like partner retention and funding concerns exist, OmniAb's strengths in technology and commitment to discovery present significant opportunities for growth.
With a strong capital position, OmniAb is well-equipped to navigate challenges and capitalize on opportunities in the biotech space. The company's emphasis on internal technology development, strategic acquisitions, and employee engagement underscores a proactive approach to sustaining leadership in antibody discovery. By leveraging their strengths and seizing opportunities, OmniAb is poised for future growth and market differentiation.
OmniAb's commitment to innovation, diverse platform, and strong capital position set the stage for continued success in antibody discovery. Challenges such as partner retention and funding uncertainties require strategic navigation. By focusing on technology development, strategic partnerships, and employee motivation, OmniAb can overcome challenges and leverage opportunities for sustained growth and market leadership.

OmniAb Inc reports strong revenue growth and strategic milestones

OmniAb Inc's Q1 2023 performance reflects robust revenue growth, strategic milestones, and a commitment to innovation in antibody discovery and development.
The company's strengths lie in its diverse host systems, proprietary platforms, strong partnerships, and scalable business model, positioning it for continued success.
While facing challenges in operational clarity and industry funding cycles, OmniAb has opportunities to drive growth through M&A, investments, and engagement with stakeholders.

OmniAb Inc reports revenue growth and strategic partnerships in Q2

OmniAb Inc's Q2 performance reflects revenue growth from new partnerships and a strong financial position with significant cash reserves
The company's technology strengths lie in its diverse host systems, successful partnerships, and innovative AI-driven tools for antibody discovery
While facing challenges like market headwinds and attrition rates, OmniAb sees opportunities in academic partnerships, regulatory changes, and ion channel programs

OmniAb Inc reports growth in partnerships but faces revenue challenges

OmniAb Inc showed growth in partnerships and programs but faced challenges with revenue and expenses in 2023.
The company's strengths lie in successful product launches, new partnerships, and a strategic focus on revenue growth sources.
Opportunities for growth include advancements in programs, lower cash use projections, and investments in new technologies.
Addressing challenges like revenue fluctuations and market uncertainties will be crucial for OmniAb's future success.

OmniAb Inc reports revenue growth and pipeline strength in Q1

OmniAb Inc's Q1 2024 performance showcased revenue growth and strong partnership developments, despite a net loss.
The company's pipeline strength, progress in clinical trials, and financial stability are key strengths driving future prospects.
Challenges include managing expenses, partner decisions impacting programs, and maintaining cash usage levels for growth initiatives.
Opportunities lie in expanding partnerships, advancing pre-clinical programs, exploring new collaborations, and leveraging positive market outlook.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

OmniAb to Participate in Three Upcoming Investor Conferences

Checkpoint Therapeutics

Performant Financial

ProQR Therapeutics

TRACON Pharmaceuticals

Analysts Say These Are Penny Stocks To Buy But Are They Worth The Risk? The post 5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks With Explosive Price Targets & Buy Ratings From Analysts

It has been a rough start for antibody discovery biotech OmniAb (US:OABI) since listing via a SPAC merger with Avista Public Acquisition Corp (US:AHPAU cnx.cmd.push(function() {var videoId = decodeURIComponent(""); cnx({ playerId: "0a52d238-33b5-4c04-ba5e-323e192cfbe8", mediaId: videoId}).render("b8b49474e42e4a61905a1353db504ac9"); });) in late October.

Is Now the Time OmniAb? 5 Insider Purchase and 2 Bullish Initiations Propel Shares Almost 100% Higher

OmniAb is an 11/2022 spinoff from Ligand Pharmaceuticals. The company has a highly differentiated and attractive business model.

OmniAb: Scalable Biotech Spinoff Opportunity, High Risk/High Reward

Butterfly Network

23andMe

Analysts say these are penny stocks to buy. Do you agree?

3 Penny Stocks To Buy According To Analysts, Targets Up To 317%

Ligand Pharmaceuticals

EMERYVILLE, Calif.--( BUSINESS WIRE )--OmniAb, Inc. (NASDAQ: OABI) reported financial results for the three and nine months ended September 30, 2022 and provided operating and program updates. OmniAb was part of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) until its spin-off as an independent publicly traded company as of November 1, 2022. As such, OmniAb will not file a Form 10-Q with the U.S. Securities and Exchange Commission (SEC) for the three months ended September 30, 2022; however, its third quarter financial results have been reported on a Form 8K/A that can be found here. Avista Public Acquisition Corp. II (which changed its name to OmniAb, Inc. in connection with the merger) filed a Form 10-Q under the name of OmniAb, Inc.

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

Aeglea BioTherapeutics

Berkeley Lights, Inc.

Invitae

Hot penny stocks to watch after October's CPI report. The post Best Penny Stocks To Buy Now That CPI Is Out?

News for OmniAb Inc Stock (OABI)